Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC.

Lancet. 2006 May 20;367(9523):1657-64.

PMID:
16714186
3.

Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis.

Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JP, Villari P.

Lancet Infect Dis. 2009 Aug;9(8):482-92. doi: 10.1016/S1473-3099(09)70153-7. Review.

PMID:
19628173
4.

A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Plosker GL.

Drugs. 2012 Jul 30;72(11):1543-57. doi: 10.2165/11209650-000000000-00000. Review.

PMID:
22788239
5.

Aflunov(®): a prepandemic influenza vaccine.

Gasparini R, Amicizia D, Lai PL, Panatto D.

Expert Rev Vaccines. 2012 Feb;11(2):145-57. doi: 10.1586/erv.11.170. Review.

PMID:
22309663
6.

A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.

Keating GM, Plosker GL, Lyseng-Williamson KA.

BioDrugs. 2012 Dec 1;26(6):425-30. doi: 10.2165/11209740-000000000-00000. Review.

PMID:
23106407
7.

Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials.

Qiu YZ, Yin WD.

Influenza Other Respir Viruses. 2008 Nov;2(6):237-42. doi: 10.1111/j.1750-2659.2008.00067.x. Review.

Supplemental Content

Support Center